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ABSTRACT  
Chlamydia trachomatis (Ct) infection causes significant morbidity. In vitro studies demonstrate 
Ct growth inhibition occurs by interferon-gamma (IFN-)-mediated depletion of intracellular 
tryptophan, and some Ct strains utilize extracellular indole to restore tryptophan levels. Whether 
tryptophan levels are associated with Ct infection in clearance humans remains unknown. We 
evaluated tryptophan, indole, and IFN- levels in cervicovaginal lavages from women with either 
naturally cleared Ct infection or persisting Ct infection. Women who cleared infection had 
significantly lower tryptophan levels and trended towards lower IFN- levels compared to women 
with persisting infection. Due to its volatility, indole was not measurable in either group. 
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BACKGROUND  
Chlamydia trachomatis (Ct) causes the most prevalent bacterial sexually transmitted 
infection worldwide [1]. Ct infection can cause chronic inflammation of the reproductive tract, 
which can lead to complications like tubal factor infertility. Despite public health efforts, Ct 
infection prevalence continues to increase [1], and our limited understanding of how Ct infection 
is cleared in humans is a hindrance to vaccine development. 
Animal models of chlamydia infection have demonstrated that interferon-gamma (IFN-) is 
essential for infection clearance [2]. Limited human studies support the role of IFN- in 
protective immunity by demonstrating an association between IFN- and protection against Ct 
reinfection [3,4]. In vitro studies demonstrate that IFN- induces depletion of intracellular 
tryptophan [5], which arrests Ct growth (as Ct is a tryptophan auxotroph) and can lead to Ct cell 
death [6]. To circumvent clearance, Ct has developed survival mechanisms. In response to 
tryptophan depletion, Ct survives by differentiating into an enlarged, non-infectious form (a 
process termed “persistence”), which results in a marked decrease in cellular metabolism and 
cellular division [7]. In addition, urogenital Ct strains encode a functional tryptophan synthase, 
which can synthesize tryptophan from extracellular precursor substrates, restoring tryptophan 
levels and permitting Ct survival in the presence of IFN--mediated immune pressure [8]. In vitro 
studies also demonstrate that indole is a precursor that can be used for tryptophan synthesis 
[8]. Although unconfirmed in vivo, this relationship may explain why bacterial vaginosis (BV), an 
infection which may include indole-producing bacteria, is associated with a 2-fold increased risk 
for incident Ct infection [9]. Whether tryptophan, indole, or IFN- levels in the genital tract are 
associated with Ct infection clearance in humans remains to be elucidated.  
To study the relationship between natural clearance of Ct infection and levels of tryptophan, 
indole, and IFN-, we evaluated levels of these compounds in cervicovaginal lavages (CVLs) 
collected from women with evidence of natural clearance of Ct infection or persisting Ct 
infection. Natural clearance of Ct infection (i.e. resolving infection before treatment) occurs in 
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approximately 11-44% of women in the interval between a positive Ct screening test and 
returning for treatment [10]. Although the mechanisms involved in natural clearance are poorly 
understood, one study reported that women who naturally cleared Ct infection were 4-fold less 
likely to be re-infected within 6 months, suggesting adaptive immunity (perhaps via IFN--
mediated tryptophan depletion) may contribute to natural clearance and protective immunity 
[11]. The primary objective of our study was to determine whether tryptophan, indole, and IFN- 
concentrations were associated with natural clearance of Ct infection in humans. A secondary 
objective was to determine whether participant characteristics or concomitant genital infections 
(e.g., BV) were associated with concentrations of these compounds.   
 
METHODS 
Study Population and Procedures. The study population consisted of females 16 years of 
age presenting to the Jefferson County Department of Health (JCDH) Sexually Transmitted 
Diseases Clinic in Birmingham, Alabama for treatment of a recent positive Ct screening nucleic 
acid amplification test (NAAT, Aptima Combo 2 [AC2]; Hologic, Marlborough, MA). All patients 
provided written consent prior to study enrollment. Women who were pregnant, had a prior 
hysterectomy, were co-infected with HIV, syphilis, or gonorrhea, or had recently received 
antibiotics with anti-Ct activity were excluded. Participants were interviewed regarding their 
demographics, symptoms, sexual history, and hormonal contraception use. A pelvic 
examination was performed to obtain a vaginal swab specimen for wet mount testing to 
diagnose trichomoniasis, BV (by Amsel’s criteria), and candidiasis and an endocervical swab 
specimen for Ct and Neisseria gonorrhoeae testing by AC2 per the manufacturer’s instructions. 
A 10 ml CVL was collected in non-menstruating women by continuously lavaging the cervix, 
posterior fornix, and vaginal walls with sterile saline for 1 minute using a 3 ml transfer pipette 
and then was stored at -80C. All study participants received directly observed therapy with 
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azithromycin 1 g PO. The study was approved by the University of Alabama at Birmingham 
(UAB) Institutional Review Board and JCDH.  
 
Multiplex. IFN- was measured in undiluted CVL supernatants using a validated multiplex 
cytokine assay (V-PLEX, Meso Scale Diagnostics, Rockville, MD) according to the 
manufacturer’s instructions.  
 
High Performance Liquid Chromatography – Mass Spectrometry. CVL cellular debris was 
removed by centrifugation at 16,100 x g for 10 minutes, followed by protein precipitation with 
four volumes of ice-cold methanol for 30 minutes, repeat centrifugation, rotor-evaporation of 
supernatants, and reconstitution of dried residues in 500 l ddH2O containing 0.1% formic acid. 
Reconstituted supernatant (10 l) was injected into a Jupiter 2.0 x 150mm, 4 µ C18 column 
(Phenomenex, Torrance, CA) and analytes resolved using a 5-95% linear gradient of 
acetonitrile in 0.1% formic acid at 400 µl/min and 50°C on a Shimadzu Prominence HPLC 
system (Shimadzu, Kyoto, Japan). Peaks corresponding to tryptophan and indole were then 
measured by multiple reaction monitoring (MRM) on a SCIEX 4000 Triple Quadrupole Mass 
Spectrometer (Concord, Ontario, Canada) in the positive ion mode.  Nebulization current was 
set at 3 with a heater interface temperature of 500°C.  Curtain and GS1/GS2 gasses were set at 
20, 50, and 5 PSI, respectively.  Tryptophan was monitored using the MRM transition of 
205.1/188.1 with a collision energy, declustering potential, entrance potential, and exit potential 
of 15 eV, 60 V, 10 V, and 12 V, respectively.  Indole was monitored using the MRM transition of 
118/91 with a collision energy, declustering potential, entrance potential, and exit potential of 20 
eV, 60 V, 10 V, and 12 V, respectively.  50 msec dwell times were used per transition. The limits 
of quantification for tryptophan and indole were 0.1 ng/ml and 1 ng/ml, respectively.  Tryptophan 
and indole concentrations were derived by comparison to known metabolite standards.  
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Statistical Analysis. Analyses were performed with SAS software, version 9.4 (SAS Institute, 
Cary, NC). Natural clearance of Ct infection was defined by a negative Ct result (by AC2) at the 
enrollment visit, while persisting infection was defined as having a positive Ct result. Participants 
defined as natural clearance who were Ct-seronegative by EB-ELISA [12] were excluded, as 
their initial positive AC2 result may reflect Ct exposure without infection. Otherwise, we tested 
all women classified as natural clearance and a 1:1 matched group of women with persisting 
infection (matched by age, race, and co-infections). The Wilcoxon signed-rank test was used to 
compare tryptophan, indole, and IFN- levels between women with naturally cleared vs. 
persisting Ct infection (matched pair groups). Associations of participant characteristics and co-
infections with cleared vs. persisting Ct infection was evaluated with the Pearson chi-square test 
or multinomial logistic regression, as appropriate. Tryptophan, indole, and IFN- levels between 
Ct infection only vs. Ct infection with a co-infection (independent of Ct clearance status for both) 
were evaluated with the Mann-Whitney-U test. Additional univariate analyses of covariates (age, 
number of partners, hormonal contraception use, and prior Ct infection) associated with 
tryptophan, indole, and IFN- levels were performed using Mann-Whitney-U tests, Spearman 
rank correlation, and Kendall’s tau-b correlation, as appropriate. A significance level of P <.05 
was used for all analyses. Only groups with n 5 were analyzed.  
 
RESULTS 
Among 245 women enrolled February 2014 – June 2016, 36 (15%) participants had natural 
clearance of Ct infection and a CVL available for testing; 36 with persisting infection and a CVL 
available were matched to them (Table 1). The median interval between screening and 
enrollment was 10 days (range 3 – 24). The median age was 25 (range 16 – 46) and 94% were 
African American. 30 (42%) women were co-infected with either BV, trichomoniasis, or 
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vulvovaginal candidiasis. No significant differences in contraception use, prior history of Ct 
infection, or interval between screening and enrollment was identified between the two groups. 
The median CVL tryptophan and IFN- levels were 36.4 ng/ml (range 0 – 815.2) and 7.0 
pg/ml (range 0 – 504.2), respectively. Compared to women with persisting Ct infection, women 
with natural clearance of Ct infection had significantly lower CVL tryptophan levels (median 25 
ng/ml vs. 54 ng/ml, P = .035, Figure 1A) and a trend towards lower IFN- levels (median 2.8 
pg/ml vs. 16.1 pg/ml, P = .076, Figure 1B). Indole levels were below the limit of detection (<1 
ng/ml) for all samples. As a control, we spiked CVL specimens with indole prior to extraction 
and did not detect indole by HPLC-MS, suggesting indole evaporated during the extraction 
process. 
Stratifying tryptophan levels in Ct-infected women (independent of Ct infection clearance 
status) by co-infection showed that co-infection with BV was associated with an almost 10-fold 
lower median CVL tryptophan level compared with Ct mono-infection (median 6.9 ng/ml vs. 67.4 
ng/ml, P <.001, Figure 1C). No significant difference in tryptophan levels between 
trichomoniasis or vaginal candidiasis and Ct mono-infection was identified. IFN- levels did not 
significantly differ comparing Ct mono-infection and co-infections (Figure 1D). 
We then evaluated the relationship between tryptophan or IFN- levels with age, race, 
hormonal contraception, or number of sex partners in the last 3 months and there were no 
significant associations found (data not shown). However, there was a trend in women with a 
history of prior Ct infection having a lower tryptophan level (median 22.8 ng/ml [range 0 – 815] 
vs. 49.0 ng/ml [0.9 – 806], P = .0561, data not shown). 
 
DISCUSSION 
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Natural clearance of Ct infection occurs slowly (~50% after one year [13]), suggesting Ct 
employs immune evasion mechanisms. Adaptive immunity likely contributes to this process, 
evidenced by the association between natural clearance of Ct infection and reduced Ct 
reinfection rates [11].  IFN- is crucial for effective Ct clearance in animal models [2], and likely 
humans [3,4], by signaling tryptophan depletion, as shown in vitro [6]. To our knowledge, our 
study is the first to provide in vivo evidence that lower cervicovaginal tryptophan levels, and 
perhaps lower IFN- levels, are associated with Ct clearance.  Together, our data suggests that 
persisting Ct infection is associated with elevated IFN- and tryptophan levels, the former likely 
reflecting the host immune response against CT and latter the organism’s effort to combat the 
IFN--mediated depletion of tryptophan by de novo synthesis of tryptophan by a functional 
tryptophan synthase. Once Ct infection is cleared, host IFN- production declines and the 
heightened tryptophan synthesis is arrested. Our finding of a trend between a history of a prior 
Ct infection, a known correlate of protective immunity [14], and 2-fold lower tryptophan levels 
suggests that heightened IFN- production in protected individuals hastens Ct clearance which 
would correlate with lower tryptophan levels.  
An interesting finding in our study was the association between BV co-infection and lower 
CVL tryptophan levels. Given the well-established association of increased Ct incidence rates in 
women with BV [9], our finding suggests that BV may use tryptophan-independent mechanisms 
to promote effective Ct immune evasion (e.g. BV biofilms, increasing vaginal pH, etc.). 
An unexpected finding was that CVL indole was not detected. This is likely due to 
evaporation during the extraction process as spiked indole was not recovered. However, 
discovery-based relative quantitation HPLC-MS pilot studies we performed (data not shown) 
confirmed the presence of high levels of other indole-containing metabolites in CVL specimens 
(e.g., indolactic acid, indoleacetyl glutamine, etc.), which have been reported by others [15]. 
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Whether these indole-containing metabolites may be a source of indole or whether indole is 
present in the cervicovaginal environment in women remains to be elucidated. 
Our study has several limitations. First, the majority of subjects were African American, 
representative of our STD clinic population, and it is unknown if vaginal tryptophan or IFN- 
levels differ between races/ethnicities. Also, our study used Amsel’s criteria to diagnose BV, 
which is less specific than the Nugent score and could have overestimated the frequency of BV 
infections. Although we excluded women classified as naturally cleared Ct infection who were Ct 
seronegative (positive AC2 from Ct exposure, but not with established infection) to minimize 
misclassification of natural clearance, it is still possible misclassification may have occurred.  
 
In summary, we demonstrated that natural clearance of Ct infection is associated with lower 
cervicovaginal tryptophan levels, and possibly lower levels of IFN-. Co-infection with BV, and 
possibly a prior Ct infection, was also associated with lower tryptophan levels. Further studies 
are needed to understand the interplay between co-infections and metabolites in the 
cervicovaginal environment.  
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FIGURE LEGENDS 
Figure 1. Cervicovaginal lavage tryptophan and IFN- concentrations in women with natural clearance 
of Ct infection vs. persisting Ct infection and also Ct mono-infection vs. co-infections. (A) Women who 
naturally cleared Ct infection had lower CVL tryptophan levels compared to women with persisting Ct 
infection (median 25 ng/ml vs. 54 ng/ml, P = .035, Fig. 1A) and a trend towards lower IFN- levels 
(median 2.8 pg/ml vs. 16.1 pg/ml, P = .076, Fig. 1B). Compared to Ct mono-infection (independent of Ct 
infection clearance status), significantly lower tryptophan levels were seen in women co-infected with BV 
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(median 6.9 ng/ml vs. 67.4 ng/ml, P <.001, Fig. 1C). IFN- levels did not differ by co-infection (Fig. 1D). 
Only co-infections with n >5 were analyzed. The horizontal line denotes the median. The Y-axis is 
shown as a logarithmic scale. 
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Cleared Ct  
(n = 36) 
Persisting Ct  
(n = 36) 
 
P-value 
Age, median (range)f 25 (16 – 46) 25 (16 – 46) 25 (16 – 46) – 
Race, n (%)f     – 
    AA         68 (94%) 34 (94%) 34 (94%)  
    Caucasian 2 (3%) 1 (3%) 1 (3%)  
    Other 2 (3%) 1 (3%) 1 (3%)  
Partners prior 3 Mo, 
median (range)d 
1 (1 – 4) 1 (1 – 3) 1 (1 – 4) 0.1399b 
Contraception, n (%)e 25 (35%) 9 (25%) 16 (46%) 0.0677c 
Prior Ct, n (%) 40 (56%) 18 (50%) 22 (61%) 0.3428c 
Co-Infection, n (%)f    – 
    None (Ct Only) 42 (58%) 21 (58%) 21 (58%)  
    BV 15 (21%) 8 (22%) 7 (19%)  
    Trichomoniasis 3 (4%) 1 (3%) 2 (6%)  
    Candida 10 (14%) 5 (14%) 5 (14%)  
Visit intervalg, median 
days (range) 
10 (3 – 24)  9 (4 – 21) 11 (3 – 24) 0.1438b 
Abbreviations: AA, African American; Ct, chlamydia infection; Mo, months; BV, bacterial vaginosis. 
aCleared Ct and Persisting Ct pairs were matched on age, race, co-infection. 
bmultinomial logistic regression. 
cPearson chi-square test. 
dData missing for 3 women.  
e Data missing for 1 woman. 
f P-value not reported as data was matched. 
gDuration (days) between screening and treatment visits. 
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